Sugi Predict

Sugi Predict / Compounds / SCHEMBL347282

SCHEMBL347282

SCHEMBL347282

Cc1nnc(-c2sc(N3CCN(Cc4ccc(F)cc4)C3=O)nc2C)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 11/20 0.60
▸ RAB9A P51151 1/20 0.48
▸ POLB P06746 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HDAC1 Q13547 1/20 0.40
▸ TP53 P04637 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ PKM P14618 1/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348823 0.90 SCD (0.55) SCDPOLBHDAC1KMT2A
SCHEMBL346232 0.89 SCD (0.48) SCDRAB9APOLBTSHRKDM4E
SCHEMBL347089 0.81 SCD (0.59) SCDRAB9APOLBTSHRKDM4E
SCHEMBL347629 0.80 SCD (0.60) SCDRAB9APOLBTSHRKDM4E
SCHEMBL243192 0.79 SCD (0.59) SCDRAB9APOLBTSHRKDM4E
SCHEMBL241052 0.76 SCD (0.82) SCDRAB9APOLBTSHRKDM4E
SCHEMBL242074 0.76 SCD (0.82) SCDRAB9APOLBTSHRKDM4E
SCHEMBL348636 0.76 SCD (0.66) SCDRAB9APOLBTSHRKDM4E
SCHEMBL242657 0.75 SCD (1.00) SCDRAB9APOLBTSHRKDM4E
SCHEMBL244959 0.73 SCD (0.77) SCDRAB9APOLBTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102007123-B Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2014-04-30 — — CN claimed
CN-102007123-B Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2014-04-30 — — CN disclosed
US-8318949-B2 Organic compounds NOVARTIS AG (CH) 2012-11-27 — — US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 — — US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 — — US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 — — US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 — — US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 — — US disclosed
CN-102007123-A Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2011-04-06 — — CN disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 — — US disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 — — US disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014906-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 SCD 1/4885RAB9A 4305/4885POLB 2337/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 SCD 1/4885RAB9A 4305/4885POLB 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.